Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1976 3
1977 6
1978 6
1979 10
1980 7
1981 18
1982 23
1983 23
1984 26
1985 34
1986 48
1987 39
1988 65
1989 90
1990 129
1991 135
1992 153
1993 165
1994 184
1995 176
1996 229
1997 260
1998 295
1999 344
2000 381
2001 479
2002 530
2003 592
2004 583
2005 725
2006 759
2007 748
2008 846
2009 893
2010 975
2011 979
2012 997
2013 1193
2014 1287
2015 1248
2016 1275
2017 1207
2018 1346
2019 1331
2020 1439
2021 1467
2022 1536
2023 1470
2024 1555
2025 1813
2026 944

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27,861 results

Results by year

Filters applied: . Clear all
Page 1
Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women.
Ridker PM, Moorthy MV, Cook NR, Rifai N, Lee IM, Buring JE. Ridker PM, et al. N Engl J Med. 2024 Dec 5;391(22):2087-2097. doi: 10.1056/NEJMoa2405182. Epub 2024 Aug 31. N Engl J Med. 2024. PMID: 39216091 Free PMC article. Clinical Trial.
BACKGROUND: High-sensitivity C-reactive protein (CRP), low-density lipoprotein (LDL) cholesterol, and lipoprotein(a) levels contribute to 5-year and 10-year predictions of cardiovascular risk and represent distinct pathways for pharmacologic interventi …
BACKGROUND: High-sensitivity C-reactive protein (CRP), low-density lipoprotein (LDL) cholesterol, and lipoprotein(a) levels co …
LDL cholesterol as a causal agent of atherosclerosis.
Pedro-Botet J, Climent E, Benaiges D. Pedro-Botet J, et al. Clin Investig Arterioscler. 2024 Dec;36 Suppl 1:S3-S8. doi: 10.1016/j.arteri.2024.07.001. Epub 2024 Jul 22. Clin Investig Arterioscler. 2024. PMID: 39043480 Free article. Review. English, Spanish.
LDL cholesterol, beyond being a cardiovascular risk factor, is a causal agent of atherosclerosis. Without LDL cholesterol there is no atherosclerosis, so the evolution of the disease is modifiable, and even reversible....
LDL cholesterol, beyond being a cardiovascular risk factor, is a causal agent of atherosclerosis. Without LDL …
Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation.
Hoogeveen RC, Ballantyne CM. Hoogeveen RC, et al. Clin Chem. 2021 Jan 8;67(1):143-153. doi: 10.1093/clinchem/hvaa252. Clin Chem. 2021. PMID: 33257928 Free PMC article. Review.
BACKGROUND: Current guidelines target low-density lipoprotein cholesterol (LDL-C) concentrations to reduce atherosclerotic cardiovascular disease (ASCVD) risk, and yet clinical trials demonstrate persistent residual ASCVD risk despite agg …
BACKGROUND: Current guidelines target low-density lipoprotein cholesterol (LDL-C) concentrations to reduce atherosclerotic …
Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 randomized controlled trials.
Burger PM, Dorresteijn JAN, Koudstaal S, Holtrop J, Kastelein JJP, Jukema JW, Ridker PM, Mosterd A, Visseren FLJ. Burger PM, et al. Atherosclerosis. 2024 Sep;396:118540. doi: 10.1016/j.atherosclerosis.2024.118540. Epub 2024 Jul 11. Atherosclerosis. 2024. PMID: 39126771 Free article.
BACKGROUND AND AIMS: Individuals with or at high risk of cardiovascular disease (CVD) often receive long-term treatment with low-density lipoprotein cholesterol (LDL-C) lowering therapies, but whether the effects of LDL-C reduction remain …
BACKGROUND AND AIMS: Individuals with or at high risk of cardiovascular disease (CVD) often receive long-term treatment …
Altered cardiovascular risk pattern of LDL cholesterol in older adults.
Rozing MP, Westendorp RGJ. Rozing MP, et al. Curr Opin Lipidol. 2023 Feb 1;34(1):22-26. doi: 10.1097/MOL.0000000000000859. Epub 2022 Nov 16. Curr Opin Lipidol. 2023. PMID: 36413436 Review.
PURPOSE OF REVIEW: Elevated serum low-density lipoprotein cholesterol (LDL-C) levels at middle-age constitute a strong risk factor for later cardiovascular events. ...We review three potential explanations for the changed cardiovascular risk …
PURPOSE OF REVIEW: Elevated serum low-density lipoprotein cholesterol (LDL-C) levels at middle-age constitute a strong risk …
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
Ray KK, Troquay RPT, Visseren FLJ, Leiter LA, Scott Wright R, Vikarunnessa S, Talloczy Z, Zang X, Maheux P, Lesogor A, Landmesser U. Ray KK, et al. Lancet Diabetes Endocrinol. 2023 Feb;11(2):109-119. doi: 10.1016/S2213-8587(22)00353-9. Epub 2023 Jan 5. Lancet Diabetes Endocrinol. 2023. PMID: 36620965 Free article. Clinical Trial.
INTRODUCTION: Whether long-term treatment with the twice-yearly, siRNA therapeutic inclisiran, which reduces hepatic production of proprotein convertase subtilisin/kexin type 9 (PCSK9), results in sustained reductions in LDL cholesterol with an acceptable safety pro …
INTRODUCTION: Whether long-term treatment with the twice-yearly, siRNA therapeutic inclisiran, which reduces hepatic production of proprotei …
LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics.
Tasdighi E, Adhikari R, Almaadawy O, Leucker TM, Blaha MJ. Tasdighi E, et al. Annu Rev Pharmacol Toxicol. 2024 Jan 23;64:135-157. doi: 10.1146/annurev-pharmtox-031023-100609. Epub 2023 Jul 28. Annu Rev Pharmacol Toxicol. 2024. PMID: 37506332 Free article. Review.
Lipoprotein(a) [Lp(a)] is a molecule bound to apolipoprotein(a) with some similarity to low-density lipoprotein cholesterol (LDL-C), which has been found to be a risk factor for cardiovascular disease (CVD). ...The future of cardiovascular …
Lipoprotein(a) [Lp(a)] is a molecule bound to apolipoprotein(a) with some similarity to low-density lipoprotein cholesterol (LDL …
Low-Density Lipoprotein Cholesterol, Cardiovascular Disease Risk, and Mortality in China.
Chen L, Chen S, Bai X, Su M, He L, Li G, He G, Yang Y, Zhang X, Cui J, Xu W, Song L, Yang H, He W, Zhang Y, Li X, Hu S. Chen L, et al. JAMA Netw Open. 2024 Jul 1;7(7):e2422558. doi: 10.1001/jamanetworkopen.2024.22558. JAMA Netw Open. 2024. PMID: 39023892 Free PMC article.
IMPORTANCE: Limited evidence supports the association between low-density lipoprotein cholesterol (LDL-C) and mortality across different atherosclerotic cardiovascular disease (ASCVD) risk stratifications. OBJECTIVE: To explore the associations …
IMPORTANCE: Limited evidence supports the association between low-density lipoprotein cholesterol (LDL-C) and mortality across …
Residual cardiovascular risk: When should we treat it?
Gomez-Delgado F, Raya-Cruz M, Katsiki N, Delgado-Lista J, Perez-Martinez P. Gomez-Delgado F, et al. Eur J Intern Med. 2024 Feb;120:17-24. doi: 10.1016/j.ejim.2023.10.013. Epub 2023 Oct 14. Eur J Intern Med. 2024. PMID: 37845117 Review.
Cardiovascular disease (CVD) still being the most common cause of death in worldwide. In spite of development of new lipid-lowering therapies which optimize low-density lipoprotein cholesterol (LDL-c) levels, recurrence of CVD events implies addressing …
Cardiovascular disease (CVD) still being the most common cause of death in worldwide. In spite of development of new lipid-low …
Aerobic, resistance, or combined exercise training and cardiovascular risk profile in overweight or obese adults: the CardioRACE trial.
Lee DC, Brellenthin AG, Lanningham-Foster LM, Kohut ML, Li Y. Lee DC, et al. Eur Heart J. 2024 Apr 1;45(13):1127-1142. doi: 10.1093/eurheartj/ehad827. Eur Heart J. 2024. PMID: 38233024 Free PMC article. Clinical Trial.
The primary outcome was the change from baseline to 1 year in the standardized composite Z-score of four well-established CVD risk factors: systolic blood pressure, low-density lipoprotein (LDL) cholesterol, fasting glucose, and per cent body fat. ...B …
The primary outcome was the change from baseline to 1 year in the standardized composite Z-score of four well-established CVD risk …
27,861 results
You have reached the last available page of results. Please see the User Guide for more information.